Macrophage in liver Fibrosis: Identities and mechanisms
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Liver fibrosis is a chronic disease characterized by the deposition of extracellular matrix and continuous loss of tissues that perform liver functions. Macrophages are crucial modulators of innate immunity and play important roles in liver fibrogenesis. Macrophages comprise heterogeneous subpopulations that exhibit different cellular functions. Understanding the identity and function of these cells is essential for understanding the mechanisms of liver fibrogenesis. According to different definitions, liver macrophages are divided into M1/M2 macrophages or monocyte-derived macrophages/Kupffer cells. Classic M1/M2 phenotyping corresponds to pro- or anti-inflammatory effects, and, therefore, influences the degree of fibrosis in later phases. In contrast, the origin of the macrophages is closely associated with their replenishment and activation during liver fibrosis. These two classifications of macrophages depict the function and dynamics of liver-infiltrating macrophages. However, neither description properly elucidates the positive or negative role of macrophages in liver fibrosis. Critical tissue cells mediating liver fibrosis include hepatic stellate cells and hepatic fibroblasts, with hepatic stellate cells being of particular interest because of their close association with macrophages in liver fibrosis. However, the molecular biological descriptions of macrophages are inconsistent between mice and humans, warranting further investigations. In liver fibrosis, macrophages can secrete various pro-fibrotic cytokines, such as TGF-β, Galectin-3 and interleukins (ILs), and fibrosis-inhibiting cytokines, such as IL10. These different secretions may be associated with the specific identity and spatiotemporal characteristics of macrophages. Furthermore, during fibrosis dissipation, macrophages may degrade extracellular matrix by secreting matrix metalloproteinases (MMPs). Notably, using macrophages as therapeutic targets in liver fibrosis has been explored. The current therapeutic approaches for liver fibrosis can by categorized as follows: treatment with macrophage-related molecules and macrophage infusion therapy. Although there have been limited studies, macrophages have shown reliable potential for liver fibrosis treatment. In this review, we focu on the identity and function of macrophages and their relationship to the progression and regression of liver fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Protective and pathogenic functions of macrophage subsets
Murray, P. J., & Wynn, T. A. (2011) · Nature Reviews Immunology · doi:10.1038/nri3073 · Cited by 5,269
Non-alcoholic fatty liver disease
Powell, E. E., Wong, V. W.-S., & Rinella, M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32511-3 · Cited by 2,789
Diversity, Mechanisms, and Significance of Macrophage Plasticity
Locati, M., Curtale, G., & Mantovani, A. (2020) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012718 · Cited by 2,199
Molecular and cellular mechanisms of liver fibrosis and its regression
Kisseleva, T., & Brenner, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00372-7 · Cited by 2,024
Tissue-Resident Macrophage Ontogeny and Homeostasis
Ginhoux, F., & Guilliams, M. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.024 · Cited by 1,884
Liver fibrosis – from bench to bedside
Friedman, S. L. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00429-4 · Cited by 1,780
Ginès, P., Krag, A., Abraldes, J. G., Solà, E., Fabrellas, N., & Kamath, P. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01374-x · Cited by 1,663
Liver inflammation and fibrosis
Koyama, Y., & Brenner, D. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88881 · Cited by 1,295
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
Macrophage heterogeneity in liver injury and fibrosis
Tacke, F., & Zimmermann, H. W. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.12.025 · Cited by 1,061
Targeting hepatic macrophages to treat liver diseases
Tacke, F. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.02.026 · Cited by 1,003
Ramachandran, P., Pellicoro, A., Vernon, M. A., Boulter, L., Aucott, R. L., Ali, A., Hartland, S. N., Snowdon, V. K., Cappon, A., Gordon-Walker, T. T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119964109 · Cited by 1,001
The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Kazankov, K., Jørgensen, S. M. D., Thomsen, K. L., Møller, H. J., Vilstrup, H., George, J., Schuppan, D., & Grønbæk, H. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0082-x · Cited by 941
TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis—Updated 2019
Dewidar, B., Meyer, C., Dooley, S., & Meindl-Beinker, A. N. (2019) · Cells · doi:10.3390/cells8111419 · Cited by 837
Meng, F., Wang, K., Aoyama, T., Grivennikov, S. I., Paik, Y., Scholten, D., Cong, M., Iwaisako, K., Liu, X., Zhang, M., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.049 · Cited by 711
Macrophage-Based Approaches for Cancer Immunotherapy
Anderson, N. R., Minutolo, N. G., Gill, S., & Klichinsky, M. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2990 · Cited by 698
Wen, Y., Lambrecht, J., Ju, C., & Tacke, F. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00558-8 · Cited by 695
Bonnardel, J., T’Jonck, W., Gaublomme, D., Browaeys, R., Scott, C. L., Martens, L., Vanneste, B., De Prijck, S., Nedospasov, S. A., Kremer, A., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.08.017 · Cited by 631
Baeck, C., Wehr, A., Karlmark, K. R., Heymann, F., Vucur, M., Gassler, N., Huss, S., Klussmann, S., Eulberg, D., Luedde, T., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300304 · Cited by 609
Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets
Zhang, C.-Y., Yuan, W.-G., He, P., Lei, J.-H., & Wang, C.-X. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i48.10512 · Cited by 594
Loomba, R., Lawitz, E., Mantry, P. S., Jayakumar, S., Caldwell, S. H., Arnold, H., Diehl, A. M., Djedjos, C. S., Han, L., Myers, R. P., et al. (2018) · Hepatology · doi:10.1002/hep.29514 · Cited by 549
Seidman, J. S., Troutman, T. D., Sakai, M., Gola, A., Spann, N. J., Bennett, H., Bruni, C. M., Ouyang, Z., Li, R. Z., Sun, X., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.001 · Cited by 443
Sakai, M., Troutman, T. D., Seidman, J. S., Ouyang, Z., Spann, N. J., Abe, Y., Ego, K. M., Bruni, C. M., Deng, Z., Schlachetzki, J. C. M., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.09.002 · Cited by 418
Tran, S., Baba, I., Poupel, L., Dussaud, S., Moreau, M., Gélineau, A., Marcelin, G., Magréau-Davy, E., Ouhachi, M., Lesnik, P., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.06.003 · Cited by 400
Daemen, S., Gainullina, A., Kalugotla, G., He, L., Chan, M. M., Beals, J. W., Liss, K. H., Klein, S., Feldstein, A. E., Finck, B. N., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2020.108626 · Cited by 378
Chalasani, N., Abdelmalek, M. F., Garcia-Tsao, G., Vuppalanchi, R., Alkhouri, N., Rinella, M., Noureddin, M., Pyko, M., Shiffman, M., Sanyal, A., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.296 · Cited by 358
Liver regeneration and inflammation: from fundamental science to clinical applications
Campana, L., Esser, H., Huch, M., & Forbes, S. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00373-7 · Cited by 307
Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis
Gao, J., Wei, B., de Assuncao, T. M., Liu, Z., Hu, X., Ibrahim, S., Cooper, S. A., Cao, S., Shah, V. H., & Kostallari, E. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.044 · Cited by 288
Ma, P.-F., Gao, C.-C., Yi, J., Zhao, J.-L., Liang, S.-Q., Zhao, Y., Ye, Y.-C., Bai, J., Zheng, Q.-J., Dou, K.-F., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.022 · Cited by 284
Macrophage autophagy protects against liver fibrosis in mice
Lodder, J., Denaës, T., Chobert, M.-N., Wan, J., El-Benna, J., Pawlotsky, J.-M., Lotersztajn, S., & Teixeira-Clerc, F. (2015) · Autophagy · doi:10.1080/15548627.2015.1058473 · Cited by 266
Dou, C., Liu, Z., Tu, K., Zhang, H., Chen, C., Yaqoob, U., Wang, Y., Wen, J., van Deursen, J., Sicard, D., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.02.015 · Cited by 240
Xiang, D.-M., Sun, W., Ning, B.-F., Zhou, T.-F., Li, X.-F., Zhong, W., Cheng, Z., Xia, M.-Y., Wang, X., Deng, X., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-313392 · Cited by 229
Aoyama, T., Inokuchi, S., Brenner, D. A., & Seki, E. (2010) · Hepatology · doi:10.1002/hep.23795 · Cited by 211
Safety profile of autologous macrophage therapy for liver cirrhosis
Moroni, F., Dwyer, B. J., Graham, C., Pass, C., Bailey, L., Ritchie, L., Mitchell, D., Glover, A., Laurie, A., Doig, S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0599-8 · Cited by 202
Hepatic Stellate Cell-Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis
Matsuda, M., & Seki, E. (2020) · Seminars in Liver Disease · doi:10.1055/s-0040-1708876 · Cited by 189
Bird, T. G., Lu, W.-Y., Boulter, L., Gordon-Keylock, S., Ridgway, R. A., Williams, M. J., Taube, J., Thomas, J. A., Wojtacha, D., Gambardella, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1302168110 · Cited by 166
Sirtuin 6—A Key Regulator of Hepatic Lipid Metabolism and Liver Health
Dong, X. C. (2023) · Cells · doi:10.3390/cells12040663 · Cited by 63
Macrophage-specific FGF12 promotes liver fibrosis progression in mice
Li, S., Zhou, B., Xue, M., Zhu, J., Tong, G., Fan, J., Zhu, K., Hu, Z., Chen, R., Dong, Y., et al. (2023) · Hepatology · doi:10.1002/hep.32640 · Cited by 62
Bartneck, M., Koppe, C., Fech, V., Warzecha, K. T., Kohlhepp, M., Huss, S., Weiskirchen, R., Trautwein, C., Luedde, T., & Tacke, F. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.08.012 · Cited by 44
Kohlhepp, M. S., Liu, H., Tacke, F., & Guillot, A. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1129831 · Cited by 27
Cited by
Central role for cholangiocyte pathobiology in cholestatic liver diseases
Jalan-Sakrikar, N., Guicciardi, M. E., O’Hara, S. P., Azad, A., LaRusso, N. F., Gores, G. J., & Huebert, R. C. (2025) · Hepatology · doi:10.1097/hep.0000000000001093 · Cited by 38
Beyond M1/M2: The role of reactive oxygen species in liver fibrosis and immune modulation
Lu, H., Huang, J., Wang, Y.-C., Casals, E., Casals, G., & Zeng, M. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103933 · Cited by 19
Shao, C., Xu, H., Sun, X., Pan, Y., Liang, X., Huang, J., He, Y., Guo, W., Ye, L., & Zhang, J. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117486 · Cited by 12
Novel regulators of hepatic macrophages in liver fibrosis
Tang, X., Bai, M., Du, X., Wang, H., Liu, M., Fu, X., Zhang, H., Liang, S., & Wang, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1705503 · Cited by 12
Deng, J.-W., Yuan, S., Shi, L.-P., Chen, X., Liu, J., Chen, Z.-W., Tan, K.-Y., Yang, Q., & Cao, W.-F. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.117730 · Cited by 12
Metadata
- Authors
- Wang, Z., Du, K., Jin, N., Tang, B., & Zhang, W.
- Venue
- International Immunopharmacology
- Publisher
- Elsevier BV
- Published
- 2023-07
- Volume
- 120
- Pages
- 110357
- ISSN
- 1567-5769 (ISSN-L)
- OpenAlex
- W4377293315
- Cited by
- 105
- References
- 40
- FWCI
- 14.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.